Arch Biopartners Inc.
ARCH.V
TSX
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -1.44M | -2.45M | -3.02M | -2.88M | -3.57M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 122.70K | 1.32M | 3.38M | 2.54M | 1.41M |
| Change in Net Operating Assets | -- | -- | -- | -- | -- |
| Cash from Operations | -1.32M | -1.13M | 364.90K | -338.40K | -2.16M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.00M | -1.00M | -1.00M | -- | -- |
| Total Debt Issued | 3.05M | 3.00M | 1.50M | 1.52M | 0.00 |
| Total Debt Repaid | -1.10M | -1.12M | -844.30K | -844.30K | -62.00K |
| Issuance of Common Stock | 128.00K | 128.00K | 128.00K | 185.00K | 794.70K |
| Repurchase of Common Stock | -201.50K | -201.50K | -424.80K | -424.80K | -424.80K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 53.00K | 53.00K | 5.30K | 12.30K | 0.00 |
| Cash from Financing | 1.43M | 1.38M | 237.50K | 311.90K | 272.40K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.80K | 241.10K | 602.30K | -26.60K | -1.89M |
